FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test
The FDA's advisory committee will meet on September 23 to review the PMA application for GRAIL's Galleri multi-cancer early detection test.
A group of experts will review GRAIL's cancer-detection test to decide if doctors can use it. This is an important checkpoint—watch how experts respond to see if the test really works as promised.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.